Extracellular vesicle biomarkers to monitor DM1 using urine and blood samples

Who could benefit from this research

What this research studies

This project follows people with DM1 over time to see if molecules in extracellular vesicles found in urine and blood reflect how the disease is progressing or responding to treatment. Researchers will collect samples at multiple visits and analyze vesicle-related RNAs, proteins, and metabolites to identify reliable biomarkers. The goal is to enable frequent, painless monitoring that could reduce the need for muscle biopsies in future trials. Participation would involve scheduled visits, sample collection, and simple questions about health and symptoms. If successful, this approach could simplify tracking disease status and drug effects for patients and clinicians.

Why it matters

Where this research is happening

• Massachusetts General Hospital
  Boston, United States Active

Researchers

• Principal investigator: Wheeler, Thurman M — Massachusetts General Hospital
• Study coordinator: Wheeler, Thurman M

Related research

Other NIH-funded projects on the same topics.

• New small molecule therapeutics to help myotonic dystrophy

  A new NIH-funded project tests specially designed small molecules to lower harmful RNA activity in myotonic dystrophy and related diseases, aiming to reduce disease-driving RNA effects.

  NIH research State University of New York at Albany · Albany, United States · NIH-11617693

• Mechanisms of muscle disease in myotonic dystrophy type 1

  This project looks at why skeletal muscles weaken and waste away in adults with myotonic dystrophy type 1 and aims to uncover the underlying molecular causes.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11597907

• Calcium Channel Blocker in DM1: Can amlodipine help myotonic dystrophy type 1

  This study tests whether the calcium‑channel blocker amlodipine can improve symptoms and survival in myotonic dystrophy type 1 (DM1).

  NIH research University of Rochester · Rochester, United States · NIH-11444061

• Preparing therapies for DM1 across ages, with a focus on children

  A broad, patient-focused effort to bring promising DM1 therapies to both children and adults by enriching trial readiness, biomarkers, and natural history data.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11423652

• Biological factors that drive variability in myotonic dystrophy

  This grant explores why myotonic dystrophy can look very different from person to person by studying its genetic changes and how they affect muscle in adults.

  NIH research University of Florida · Gainesville, United States · NIH-11404431

• Identifying RNA Splicing and Gene Expression Changes in congenital myotonic dystrophy

  This grant looks at how RNA changes contribute to congenital myotonic dystrophy to understand why symptoms change as children grow.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11393159

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.